Quarterly report pursuant to Section 13 or 15(d)

Organization and Summary of Significant Accounting Policies (Details Narrative)

v3.19.1
Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Jan. 02, 2019
Dec. 31, 2018
Dec. 31, 2017
Accumulated deficit $ (8,374,966)     $ (7,624,134)  
Net income loss (750,832) $ (1,096,798)      
Net cash used in operating activities (492,429) (1,069,008)      
Cash and cash equivalents 1,248,532 $ 1,776,639   1,740,961 $ 2,847,429
Clinical Trial Funding commitment from investor capital 1,700,000        
Payments made directly by investor for clinical trial costs 115,000        
Impairment of Long-Lived Assets        
Right-of-use asset 275,251   $ 293,198  
Lease obligations 283,885   $ 303,161    
Contract Research Organization [Member]          
Payments made directly by investor for clinical trial costs $ 216,965